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Abstract Contro-versial experiments have been published on calmodulin binding of dystrophin. In this study, we used recombinant proteins and 
the techniques of affinity chromatography and ELISA to show that the N-terminal part of dystrophin binds calmodulin specifically in a calcium- 
dependent manner. The calcium-dependent interaction of calmodulin and dystrophin does not directly regulate binding of actin to dystrophin, but 
may regulate dystrophin interactions with other associated proteins. 
Key words: Duchenne muscular dystrophy; Dystrophin; Cahnodulin; Actin; Recombinant protein 
1. Introduction 
Dystrophin is a 400 kDa elongated protein coded by a gene 
located on Xp21 [l]. It is a low quantity protein representing 
0.002% of total muscular cell proteins [2], but is essential for 
the membrane integrity of the cell. Its absence causes Duchenne 
muscular dystrophy @MD), a progressive lethal disease [3]. 
Immunocytochemical studies have shown that it is localized on 
the cell membrane where it binds an integral membrane com- 
plex of glycoproteins that link the extracellular domain via the 
laminin-M receptor [4,5]. The role of dystrophin in this DMD 
dysfunction has yet to be elucidated, but two hypotheses are 
commonly put forth: the first suggests that dystrophin has a 
role in stabilizing the sarcolemmal membrane and the second 
a role in regulating the intracellular calcium concentration [6,7]. 
There is now evidence which suggests that an absence of 
dystrophin may upset calcium levels. An elevated level of intra- 
cellular calcium has been reported in DMD muscle cells [8,9], 
leading to an increased protein degradation rate in the cell 
[8, lo]. An increase in the parvalbumin concentration was noted 
in muscle tissue from mdx mice [l 11, and an increased calmod- 
ulin (CaM) level was observed in dystrophic hamsters and in 
DMD muscles [12,13]. 
CaM is a small heat-stable calcium-binding protein found in 
most eucaryotic cells. CaM is implicated in many cellular proc- 
esses such as regulation of cell motility, cyclic nucleotide levels 
or calcium fluxes [ 14,151. The binding of CaM to dystrophin has 
already been investigated but the results are controversial. 
Madhavan et al. proposed two consensus sequences, one lo- 
cated in the N-terminal part of dystrophin and the other in the 
C-terminal part of the molecule 1161. To partially address this 
point, we investigated possible CaM binding to the N-terminal 
part of dystrophin using a soluble recombinant protein de- 
signed in our laboratory, rather than the full length protein. 
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Moreover, we investigated its possible regulation of dystro- 
phin-actin interactions. 
2. Experimental 
2.1. Protein preparations 
Proteins were purified by previously described methods: bovine brain 
calmodulin [ 17, rabbit skeletal actin [ 181 with slight modifications [191, 
recombinant proteins of human dystrophin, named A0 (first 43 1 resi- 
dues), A01 (first 68 residues), A02 (residues 49 to 431) and nonrecom- 
binant protein (NR) [20]. These constructions consist of a 42 kDa 
N-terminal part, corresponding to the maltose binding protein (MBP), 
and a C-terminal part, corresponding to the dystrophin fragments men- 
tioned above, except for the NR whose C-terminal part contained a 
9 kDa /?-galactosidase fragment. 
2.2. Calmodulin-Sepharose column 
Proteins were dialysed against a 20 mM imidazole, pH = 7.0, 10 mM 
KCl, 2 mM MgC&, 0.1 mM DlT, 2 mM CaClz buffer (A), loaded on 
a 1 x 10 cm column of calmodulin-Sepharose4B (Pharmacia, Uppsala 
Sweden), washed several times in the same buffer then with an imi- 
daxole salt buffer (B) and eluted with the above imidazole buffer (C) 
containing 5 mM EGTA. 
2.3. Immunological techniques 
ELISA was carried out by the method of Engvall [21]. Proteins 
(F-actin and calmodulin) were coated at 200 &ml and 10 &nl, 
respectively, on microtitre plate wells (Nunc) and incubated overnight 
at 4°C. After washing with PBS-Tween, wells were saturated with 1% 
BSA-PBS. Fusion proteins were incubated for 1 hat 37°C in decreasing 
concentrations. For actincoated plates, CaM was applied at 1 mg/ml 
in 5 mM CaCl, or EGTA for 1 h at 37’C. The lirst antibody used, 4E8, 
is a monoclonal antibody raised against MBP protein which was pro- 
duced and characterized in the laboratory. The second antibody is an 
alkaline phosphatase conjugated anti-mouse antibody diluted as rec- 
ommended by the manufacturer (Jackson Immuno Reseach). 
2.4. Actin-binding 
Skeletal muscle actin (20 PM) and N-terminal recombinant dystro- 
phin (5 PM) were mixed at 2S°C in 20 mM Tris-HCl, pH = 7.5,2 mM 
M&l,. 1 mM DTT. 1 mM ATP with CaM (10 uM) CaCI, or EGTA 
(2 mM). Samples (0.1 ml) were then centrifuged at 30’PSI ina Beckman 
airfuge, 30 min at 2O’C. Pellets and supematants were subjected to 
SDS-PAGE. 
2.5. Other procedures 
Protein concentrations were determined by spectrophotometric 
measurements in a Kontron Uvikon 930 using the following extinction 
coefficients: CaM E&%~ = 1.9 [22], actin &&, = 11 [23], except for 
recombinant proteins whose concentrations were measured by the 
Bradford Assay using BSA for calibration [24]. 
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3. Results 
3.1. Calmodulin binding to the N-terminal part of dystrophin 
NR and the three fragments A0(1-431), A01(148), A02(49- 
431) were applied to a calmodulin-Sepharose column under 
high and low ionic strength conditions (Fig. 1). Each fraction, 
absorbing at 280 nm, was identified on Coomassie blue stained 
gel. A0 specifically bound the CaM-Sepharose column since 
elution only occurred in the presence of EGTA (buffer C), and 
not with ionic strength buffer (buffer B) (Fig. 1A). We obtained 
the same profile with A01 and A02 (Fig. lB,C). On the other 
hand, NR did not bind the affiity resin at all (Fig. lD), show- 
ing that binding of AO, A01 and A02 was specific to the dystro- 
phin part of the recombinant protein. 
Secondly, the interaction of recombinant proteins with 
coated CaM was investigated by a direct ELISA technique and 
the presence of dystrophin fused proteins was detected by anti- 
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MBP antibody. Each recombinant protein was incubated at 
concentrations ranging from 0.001 mg/ml to 0.75 mg/ml in the 
presence or absence of calcium (Fig. 2). The results clearly 
showed binding of A0 to CaM in the presence of calcium, but 
not in its absence. A01 and A02 bound coated CaM in the same 
manner (data not shown). 
3.2. Calcium-calmodulin induced modulation of the dystrophin- 
actin interface 
Since the N-terminal part of dystrophin is known to bind 
actin [20,25], we investigated how this dystrophin-actin interac- 
tion might be disturbed by the presence of the calcium+ahnod- 
ulin complex. In cosedimentation assays, actin, recombinant 
proteins and CaM, in presence or absence of calcium, were 
mixed together in a molar ratio of actin/recombinant protein/ 
CaM = 4/l/2. A0 cosedimented with actin (Fig. 3, lanes 4 and 
5) but A0 was not disturbed by the presence of calcium-CaM, 
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Fig. 1. Binding of dystrophin recombinant proteins A0 (A), A01 (B), A02 (C) and NR (D) to immobilized cahnodulin. 1 to 1.5 mg of AO, AOl, A02 
or NR was dialyzed against buffer A (see section 2) and applied on a 1 x 10 cm CaM-sepharose4B column. The column was washed and buffer 
A + 0.3 M KC1 (buffer B) was applied. Bound protein was eluted with buffer C ( 5 mM EGTA) and buffer D (5 mM EGTA + 0.3 M KC]). Buffer 
was added at the point indicated by the arrow. The inset shows 12.5% SDS-PAGE analysis of fractions 33, 45, 27 or 2 corresponding to the AO, 
AOl, A02 material removed by EGTA (A, B or C) or unbound material (D). The positions of M, markers (as Fig. 3) are shown. 
nor was CaM cosedimented with A0 and actin (Fig. 3, lane 6 
and 7). The difference in the motility of CaM in lanes 6s and 
7s was due to the binding of calcium to the molecule. In the 
same way, using the ELISA technique, binding of recombinant 
proteins on coated actin was not disturbed by calciumCaM 
(Fig. 4). 
4. Discussion 
Madhavan et al. [16] revealed the presence of two putative 
CaM-binding domains on dystrophin, one located in the N- 
terminal part of dystrophin at position 1842 and the other in 
the C-terminal part at position 3,3743,398. We thus used re- 
combinant proteins from the N-terminal part of human dystro- 
phin, which were already used in our laboratory for their actin- 
binding properties [20], to investigate binding of the N-terminal 
part of dystrophin with calciumCaM. 
We show that binding of A0 (l-431), A01 (l-68) and A02 
(49-431) to CaM is not only specific to the dystrophin part of 
the molecules (NR did not bind), but is also calcium-dependent. 
Binding of dystrophin to CaM has already been shown using 
an overlay technique, but this result was refuted by other au- 
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Fig. 2. Interaction of dystrophin recombinant protein A0 with CaM. 
In direct ELISA experiments, interaction of increased A0 concentra- 
tions (0.001 to 0.75 mg/ml) with coated C?aM in the presence of CaCl, 
(0) or EGTA (A) was followed at 405 nm with monoclonal anti-MBP 
antibody (n = 3). 
thors using the same technique [16,26]. We used CaM-sepha- 
rose and ELISA techniques and found that the N-terminal part 
of dystrophin unquestionably possesses a CaM-binding site. 
This is relevant in view of the recent paper of Madhavan and 
Jarrett [271 which showed CaM-activated phosphorylation of 
dystrophin in the C-terminal part of the molecule but not in the 
N-terminal part. CaM-binding to the N-terminal part of 
dystrophin may allow phosphorylation of the C-terminal part 
of the same, or adjacent, dystrophin molecule in view of the 
latest model of Matsumura and Campbell [28]. 
We also show here that the function of this binding is not for 
regulation of the dystrophin-actin interface, since cosediienta- 
tion and ELISA experiments did not show any modulation. 
Recombinant proteins seemed to more strongly bind actin than 
CaM, and we did not see any ternary complex in cosedimenta- 
tion analyses. 
An important question in the light of these results is where 
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Fig. 4. Modulation of the dystrophin N-terminal recombinant protein- 
actin interface with calcium-calmodulin. A direct ELLSA experiment 
was carried out as described in section 2. F-actin was coated at 200 
@ml, NR, AO, A01 and A02 were incubated for 1 h at 0.3 mg/ml (a), 
wells were washed and CaM was also incubated for 1 h at 1 mglml with 
5 mM of CaCl, (0) or EGTA (et) (n = 3). 
the CaM binding site is located (Fig. 5). The putative site is 
situated between residues 18 to 42 which overlap with the actin- 
binding site 1 (ABSl) corresponding to residues 17 to 28 [29]. 
However, A02 also binds CaM, so are there one or two sites 
in AO? If there is a single interaction site, it must be in the 
overlap region between A01 and A02 and so between residues 
49 and 68 (Fig. 5a). However, this region is not an optimal 
sequence for CaM interactions [30]. If there are two CaM 
binding sites, there should be one in the A01 sequence and 
another in the A02 sequence (Fig. 5b). Since in our cosedimen- 
tation conditions we found no ternary complex (actin-recombi- 
nant proteinCaM) these sites should overlap with ABSl and 
ABS2. 
Ervasti and Campbell [26] showed no binding of a dystro- 
phin-glycoprotein complex with calcium_CaM using the CaM- 
Sepharose affmity precipitation technique. This suggests that 
CaM binding may have a modulatory effect on the interface of 
dystrophin with one of the DAG (dystrophin associated 
aAo 
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a 
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Fig. 3. Binding of dystrophin recombinant protein A0 to actin and its modulation by calcium-calmodulin. AO-actin and CaM were cosedimented 
at 200,000 x g for 30 min in a Beckman airfuge. Supematants (S) and pellets (P) were analysed by SDS-PAGE. St: standards (M, in kDa); lanes 1 
and 2: actm alone (20 PM) with (1) or without calcium (2); lane 3: A0 alone (5 ,uM); lanes 4 and 5: actin + A0 with (4) or without (5) calcium; lanes 
6 and 7: actin + A0 + CaM (10 mM) with (6) or without (7) calcium. 
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Fig. 5. Hypothetical ocaliition of calmodulin binding sites on dystrophin N-terminal recombinant proteins. (a) Calmodulin binding site (CaMBS) 
is unique in the overlap region between A01 and AO2; (b) two CaMBS: CaMBSl corresponds to the putative CaMBS described by [16]. A0 (Iirst 
431 residues), A01 (first 68 residues) and A02 (residues 49 to 431). Boxes in black represent actin binding sites (ABS), shaded boxes represent CaMBS. 
glycoproteins) or DAP (dystrophin associated proteins), and 
more particularly with 43 kDa @-dystroglycan) or 59 kDa 
(syntrophiu-I) proteins, as mediated by phosphorylation of the 
C-terminal of dystrophiu. 
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